Morgan Stanley raises Eli Lilly & Co. price target to new Street high
Analysts said the company's Mounjary supply is ramping, and they were encouraged by LLY's commentary on its 3Q call regarding"LLY indicated that there are no issues with the Tirzepatide obesity submission or with manufacturing, which in our view was encouraging," the analysts said.
"In discussing the decision to provide guidance on the 4Q23 call vs. in December as originally planned, LLY noted that they wanted details on full year performance before giving next year guidance similar to the practice of peer companies. LLY declined to provide additional color as to its branding/pricing strategy in obesity," they added.
The investment bank continues to assume obesity pricing is on par with Mounjaro in Type 2 diabetes,"hence pricing in line with Novo's Wegovy represents a potential source of upside," the analysts wrote.We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other.
{username} Just Now Share Follow this postUnfollow this post Save Saved. See Saved Items . This comment has already been saved in your Saved Items Author's response{commentContent} Reply 00 Report {username} Just NowAuthor's response Share Follow this postUnfollow this post Save Saved. See Saved Items .
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly's stock rises as results beat expectations, Mounjaro sales surgeDrugmaker trims full-year outlook as it digests a string of recent acquisitions
Read more »
Here are Thursday's biggest analyst calls: Amazon, Sunrun, Qualcomm, Eli Lilly, SolarEdge, Estee Lauder & moreHere are Thursday's biggest calls on Wall Street.
Read more »
Novo Nordisk, Eli Lilly rake in cash from weight-loss drugsNovo Nordisk and Eli Lilly reported booming sales from their blockbuster diabetes and weight-loss drugs as both race to keep up with consumer demand.
Read more »
Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.The remarks suggest that Eli Lilly's initial efforts to expand manufacturing capacity for Mounjaro are paying off as demand for the diabetes treatment soars.
Read more »
Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.The remarks suggest that Eli Lilly’s initial efforts to expand manufacturing capacity for Mounjaro are paying off as demand for the diabetes treatment…
Read more »
Stocks making the biggest moves midday: Starbucks, Roku, Eli Lilly, Affirm and moreThese are the stocks posting the largest moves in midday trading.
Read more »